Alexandria Capital’s Antares Pharma, Inc. ATRS Stock Holding History

Alexandria Capital’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-300	Closed	-$1K	–	654
2015 Q1	$1K	Buy	+300	New	+$761	﹤0.01%	607

Other funds holding ATRS

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return

Alexandria Capital's ATRS Position: Q2 2015 in Review

Alexandria Capital sold out of Antares Pharma, Inc. (ATRS) in Q2 2015, closing a stake of 300 shares — an estimated $1K sold.

Alexandria Capital first reported a position in ATRS in Q1 2015 and held it in 1 quarter. The position peaked at $1K in Q1 2015. 88 funds tracked by Wall St. Rank hold ATRS as of Q2 2015.

Alexandria Capital reported no remaining Antares Pharma, Inc. position as of Q2 2015 after selling out during the quarter.
Alexandria Capital sold 300 Antares Pharma, Inc. shares in Q2 2015, an estimated $1K.
Alexandria Capital first reported a position in Antares Pharma, Inc. in Q1 2015 and held it in 1 quarter.
Alexandria Capital's Antares Pharma, Inc. position peaked at $1K in Q1 2015.
88 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2015.

Based on Alexandria Capital's 13F filing for Q2 2015, filed 24 Jul 2015.